Literature DB >> 22286396

CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.

Ioannis A Voutsadakis1, Panagiotis J Vlachostergios, Danai D Daliani, Foteini Karasavvidou, Grigorios Kakkas, George Moutzouris, Michael D Melekos, Christos N Papandreou.   

Abstract

INTRODUCTION: The cell surface endopeptidase CD10 (neutral endopeptidase) and nuclear factor-κB (NF-κB) have been independently associated with prostate cancer (PC) progression. We investigated the correlations between these two factors and their prognostic relevance in terms of biochemical (prostate-specific antigen, PSA) relapse after radical prostatectomy (RP) for localized PC. PATIENTS AND METHODS: The immunohistochemical expression of CD10 and NF-κB in samples from 70 patients who underwent RP for localized PC was correlated with the preoperative PSA level, Gleason score, pathological stage and time to PSA failure.
RESULTS: CD10 expression was inversely associated with NF-κB expression (p < 0.001), stage (p = 0.03) and grade (p = 0.003), whereas NF-κB was directly related with stage (p = 0.006) and grade (p = 0.002). The median time to PSA failure was 56 months. CD10 and NF-κB were directly (p < 0.001) and inversely (p < 0.001) correlated with biochemical recurrence-free survival, respectively. CD10 expression (p = 0.022) and stage (p = 0.018) were independently associated with time to biochemical recurrence.
CONCLUSION: Low CD10 expression is an adverse prognostic factor for biochemical relapse after RP in localized PC, which is also associated with high NF-κB expression. Decreased CD10 expression which would lead to increased neuropeptide signaling and NF-κB activity may be present in a subset of early PCs.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286396     DOI: 10.1159/000335299

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  8 in total

1.  Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers.

Authors:  Steven M Lucas; Elisabeth I Heath
Journal:  Prostate Cancer       Date:  2012-08-28

2.  The Stromal Overexpression of CD10 in Invasive Breast Cancer and its Association with Clincophathologic Factors.

Authors:  Ali Taghizadeh-Kermani; Amir Hossein Jafarian; Reza Ashabyamin; Mehdi Seilanian-Toosi; Leila Pourali; Mehdi Asadi; Leila Mashhadi
Journal:  Iran J Cancer Prev       Date:  2014

3.  Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.

Authors:  Andrée-Anne Grosset; Véronique Ouellet; Christine Caron; Gabriela Fragoso; Véronique Barrès; Nathalie Delvoye; Mathieu Latour; Armen Aprikian; Alain Bergeron; Simone Chevalier; Ladan Fazli; Neil Fleshner; Martin Gleave; Pierre Karakiewicz; Louis Lacombe; Jean-Baptiste Lattouf; Theodorus van der Kwast; Dominique Trudel; Anne-Marie Mes-Masson; Fred Saad
Journal:  PLoS Med       Date:  2019-07-02       Impact factor: 11.069

4.  Stromal CD10 expression in gastric adenocarcinoma.

Authors:  Sara Jalal Aziz; Jalal Ali Jalal; Kalthuma Saleh Hamadameen
Journal:  J Med Life       Date:  2022-05

Review 5.  Current status of biomarkers for prostate cancer.

Authors:  Vicki M Velonas; Henry H Woo; Cristobal G dos Remedios; Stephen J Assinder
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

6.  Prognostic significance of the combined expression of neutral endopeptidase and dipeptidyl peptidase IV in intrahepatic cholangiocarcinoma patients after surgery resection.

Authors:  Jianyong Zhu; Xiaodong Guo; Baoan Qiu; Zhiyan Li; Nianxin Xia; Yingxiang Yang; Peng Liu
Journal:  Onco Targets Ther       Date:  2014-02-17       Impact factor: 4.147

7.  CD10-Equipped Melanoma Cells Acquire Highly Potent Tumorigenic Activity: A Plausible Explanation of Their Significance for a Poor Prognosis.

Authors:  Junna Oba; Takeshi Nakahara; Akiko Hashimoto-Hachiya; Min Liu; Takeru Abe; Akihito Hagihara; Takehiko Yokomizo; Masutaka Furue
Journal:  PLoS One       Date:  2016-02-16       Impact factor: 3.240

Review 8.  Role of B Cell Development Marker CD10 in Cancer Progression and Prognosis.

Authors:  Deepshikha Mishra; Sunita Singh; Gopeshwar Narayan
Journal:  Mol Biol Int       Date:  2016-11-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.